ArticleAmerican journal of translational research2025
Value of a multi-indicator model combining Elast PQ technology, blood lipids, liver function, and uric acid for early diagnosis of alcoholic fatty liver disease.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo develop and validate a risk prediction model for alcoholic fatty liver disease (AFLD) based on clinical characteristics and liver stiffness measurements.
methodsThis retrospective cohort study included 148 AFLD patients and 148 healthy controls from a tertiary hospital between January 2018 and December 2023. Participants underwent biochemical tests (lipid profile, liver function, uric acid) and liver stiffness measurements using Elastography Protocol for Quantification (Elast PQ). The external validation cohort, was from another hospital, with data collected from May 2019 to December 2023. It included 90 patients diagnosed with AFLD and 90 healthy controls. Machine learning methods (random forest, support vector machine, logistic regression) were employed to compare model performance. Logistic regression was used to identify predictive factors. Model performance was evaluated using Receiver Operating Characteristic (ROC) curve analysis, confusion matrices, calibration curves, and Decision Curve Analysis (DCA).
resultsUnivariate analysis revealed significant associations between body mass index (BMI), alcohol consumption, blood lipids, and liver function with AFLD (P < 0.001). Multivariate analysis identified high-aensity lipoprotein (HDL) (P = 0.041), alanine aminotransferase (ALT) (P = 0.007), and Elast PQ (P = 0.038) as independent risk factors. The logistic regression model showed an area under the curve (AUC) of 0.81 in the training set, 0.67 in the validation set, and 0.79 in the external validation cohort. The optimal cutoff value of 0.403 maximized sensitivity (0.62) and specificity (0.69), with an accuracy of 0.66. DCA indicated a high clinical net benefit. The risk prediction score enables rapid AFLD risk assessment and demonstrates strong predictive ability.
conclusionsThe AFLD risk prediction model, based on clinical features and liver stiffness assessment, exhibits strong predictive power and significant clinical value for early diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.